Rosiglitazone (CAS 122320-73-4) Supplier Information and Product Details

Rosiglitazone is a thiazolidinedione antidiabetic drug used to lower blood glucose levels in patients with type 2 diabetes mellitus. It functions as an insulin sensitizer by binding to peroxisome proliferator-activated receptor gamma (PPARγ), making cells more responsive to insulin. Rosiglitazone is typically taken once or twice daily with or without food and may be used as monotherapy or in combination with other antidiabetic medications.

Frequently Asked Questions about Rosiglitazone

Q: What is the primary use of Rosiglitazone?

A: Rosiglitazone is primarily used to treat type 2 diabetes mellitus by improving insulin sensitivity in peripheral tissues.

Q: Can Rosiglitazone be used with insulin?

A: Using rosiglitazone with insulin is generally not recommended as it could increase the risk of heart failure. Patients should consult their healthcare provider for personalized advice.

Q: Are there any contraindications for Rosiglitazone use?

A: Rosiglitazone should not be used in patients with heart failure with symptoms or moderate to severe heart failure. It's important to discuss any pre-existing conditions with a healthcare provider before starting treatment.

Q: How does Rosiglitazone work?

A: Rosiglitazone is a PPARγ agonist that modulates gene expression, primarily increasing insulin sensitivity in peripheral tissues, thereby lowering blood glucose levels.

Q: What are the potential side effects of Rosiglitazone?

A: Rosiglitazone may cause a modest increase in low-density lipoprotein and triglyceride concentrations. However, the long-term clinical significance of these effects is unclear. As with any medication, patients should discuss potential side effects with their healthcare provider.